Clinical Trial: Neurokinin (NK) 1 Antagonist for Pathological Aggression for Harmful, Impulsive, and Self-/Aggressive Behaviour

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: NK1 Antagonists for Pathological Aggression: A Protocol for Harmful, Impulsive, and Self-/Aggressive Behavior (AHIMSA-1) Trial

Brief Summary: Neurokinin (NK) -1 antagonist will be administered to study patients in a double-blind placebo trial. Patients receive assessments including Anger Disorder Scale (ADS) and Modified Overt Aggression Scale (MOAS) and perform computerized study tasks during MRI before the trial begins. Patients receive either one week of the drug or one week of placebo and perform the same tasks and assessments. Then patients receive another week of the alternate pill, followed by another round of tasks during MRI and assessments.

Detailed Summary:
Sponsor: St. Joseph's Healthcare Hamilton

Current Primary Outcome: Change in Modified Overt Aggression Scale [ Time Frame: 1 week ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

• Change in Ball passing task [ Time Frame: 1 week ]
  computer task
• Change in Point Subtraction Aggression Task (PSAT) [ Time Frame: 1 week ]
  Computer task
• Change in Anger Disorders Scale (ADS) [ Time Frame: 1 week ]
• Change in Buss-Perry Aggression Questionniare (BPAQ) [ Time Frame: 1 week ]
• Change in State-Trait Anger Expression Inventory [ Time Frame: 1 week ]

Original Secondary Outcome: Same as current

Information By: St. Joseph's Healthcare Hamilton

Dates:
Date Received: November 23, 2016
Date Started: January 2017
Date Completion: January 2018
Last Updated: December 8, 2016
Last Verified: December 2016